Xin Lang Cai Jing·2026-03-17 06:21Core Viewpoint - Tiger Med's stock price has experienced a decline of 6.08% year-to-date, with significant drops in the last 5 days (7.87%) and 20 days (18.80%) [5] Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province [6] - The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products, covering I to IV phase clinical trial technical services, data management and statistical analysis, registration application, clinical trial site services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [6] - The revenue composition includes 52.60% from clinical trial-related services and laboratory services, 45.21% from clinical trial technical services, and 2.19% from other services [6] Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 50.26 billion yuan, a year-on-year decrease of 0.82%, while the net profit attributable to shareholders increased by 25.45% to 10.20 billion yuan [2][6] - The company has distributed a total of 24.58 billion yuan in dividends since its A-share listing, with 11.54 billion yuan distributed in the last three years [3][6] Shareholder Information - As of September 30, 2025, the number of shareholders is 48,400, a decrease of 6.01% from the previous period [2][6] - Major shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 25.10 million shares, and other funds such as China Europe Medical Health Mixed A and Huabao CSI Medical ETF, with varying changes in their holdings [7]